Search

Displaying results 2951 - 2960 of 4539 in total
  1. Drug

    Pimicotinib

    go.drugbank.com/drugs/DB18972
    Investigational

    It was initially developed by Abbisko Therapeutics Co in collaboration with Merck KGaA. [L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753]

  2. Drug

    Ketobemidone

    go.drugbank.com/drugs/DB06738
    Investigational

    The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection.

  3. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    Efonidipine is a calcium channel blocker of the _dihydropyridine class_, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, _Landel_.

  4. Drug

    Nisoxetine

    go.drugbank.com/drugs/DB09186
    Experimental

    It was originally investigated as an antidepressant but has no current clinical applications aside from being a research standard SNRI.

  5. Drug

    Betaprodine

    go.drugbank.com/drugs/DB01473
    ExperimentalIllicit

    An opioid analgesic chemically related to and with an action resembling that of meperidine, but more rapid in onset and of shorter duration.

  6. Drug

    Lasalocid

    go.drugbank.com/drugs/DB11423
    ExperimentalVet approved

    It is produced by strains of _Streptomyces lasaliensis_.

  7. Drug

    LS11

    go.drugbank.com/drugs/DB05918
    Investigational

    After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death.

  8. Drug

    Acrylic Acid

    go.drugbank.com/drugs/DB02579
    Investigational

    A α,β-unsaturated monocarboxylic acid that is ethene substituted by a carboxy group.

  9. Drug

    PH-284

    go.drugbank.com/drugs/DB05452
    Experimental

    PH-284 is under investigation by Pherin and Organon for the treatment of anorexia nervosa, and loss of appetite and cachexia in cancer and AIDS patients. … This binding produces neural impulses that are transmitted by specific pathways to the hypothalamic centre that directly and rapidly affect brain function.

  10. Drug

    AEOL-10150

    go.drugbank.com/drugs/DB05874
    Experimental

    AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.